Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,062.70 | 59.80 | -0.66% |
CAC 40 | 7,786.98 | 31.24 | -0.40% |
DAX 40 | 23,359.18 | 29.94 | 0.13% |
Dow JONES (US) | 46,018.32 | 260.42 | 0.57% |
FTSE 100 | 9,208.37 | 12.71 | 0.14% |
HKSE | 26,851.03 | 412.52 | 1.56% |
NASDAQ | 22,261.33 | 72.63 | -0.33% |
Nikkei 225 | 45,277.43 | 375.16 | 0.84% |
NZX 50 Index | 13,132.39 | 102.50 | -0.77% |
S&P 500 | 6,600.35 | 6.41 | -0.10% |
S&P/ASX 200 | 8,780.30 | 68.20 | -0.77% |
SSE Composite Index | 3,885.81 | 9.47 | 0.24% |